Roche to pay Simcere $75 million upfront for blood cancer drug rights
Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, Simcere said Tuesday.
Switzerland's Roche BX:RHO will pay $75 million upfront to Simcere Pharmaceutical Group HKEX:2096 for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.